دورية أكاديمية
Cost-effectiveness of HLA-B*58:01 testing to prevent Stevens-Johnson syndrome/toxic epidermal necrolysis in Vietnam.
| العنوان: | Cost-effectiveness of HLA-B*58:01 testing to prevent Stevens-Johnson syndrome/toxic epidermal necrolysis in Vietnam. |
|---|---|
| المؤلفون: | Duong KN; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA., Nguyen DV; Department of Internal Medicine, Respiratory, Allergy & Clinical Immunology Unit, Vinmec Healthcare System, Hanoi, Vietnam.; College of Health Sciences, Vin University, Hanoi, Vietnam.; Department of Medicine, Penn State University, Hershey, PA 17033, USA., Chaiyakunapruk N; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA.; IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT 84108, USA., Nelson RE; IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT 84108, USA.; Division of Epidemiology, School of Medicine, University of Utah, Salt Lake City, UT 84108, USA., Malone DC; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA. |
| المصدر: | Pharmacogenomics [Pharmacogenomics] 2023 Aug; Vol. 24 (13), pp. 713-724. Date of Electronic Publication: 2023 Sep 14. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 100897350 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8042 (Electronic) Linking ISSN: 14622416 NLM ISO Abbreviation: Pharmacogenomics Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Future Medicine Ltd Original Publication: London : Ashley Publications, |
| مستخلص: | Background: HLA-B*58:01 is strongly associated with allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in Vietnam. This study assessed the cost-effectiveness of this testing to prevent SJS/TEN. Methods: A model was developed to compare three strategies: no screening, use allopurinol; HLA-B*58:01 screening; and no screening, use probenecid. A willingness-to-pay of three-times gross domestic product per capita was used. Results: Compared with 'no screening, use allopurinol', 'screening' increased quality-adjusted life-years by 0.0069 with the incremental cost of Vietnam dong (VND) 14,283,633 (US$617), yielding an incremental cost-effectiveness ratio of VND 2,070,459,122 (US$89,398) per quality-adjusted life-year. Therefore, 'screening' was unlikely to be cost-effective under the current willingness-to-pay. Testing's cost-effectiveness may change with targeted high-risk patients, reimbursed febuxostat or lower probenecid prices. Conclusion: The implementation of nationwide HLAB*58:01 testing before the use of allopurinol is not cost-effective, according to this analysis. This may be due to the lack of quality data on the effectiveness of testing and costing data in the Vietnamese population. |
| فهرسة مساهمة: | Keywords: HLA-B*58:01; Vietnam; allopurinol-induced SJS/TEN; cost–effectiveness; genetic testing |
| تواريخ الأحداث: | Date Created: 20230914 Latest Revision: 20231012 |
| رمز التحديث: | 20240628 |
| DOI: | 10.2217/pgs-2023-0095 |
| PMID: | 37706247 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8042 |
|---|---|
| DOI: | 10.2217/pgs-2023-0095 |